We are excited to share that we will join the ESMO Congress, a globally influential oncology platform for clinicians, researchers, patient advocates, journalists and healthcare industry representatives from all over the world.
At Alira Health, we advise companies with our extensive and cross-functional expertise, including market access, pricing, real-world evidence, and transaction advisory. Take this opportunity to connect with our delegates and discover how we can help you accelerate innovation and deliver tomorrow’s standard of care for oncology patients.
Want to connect at ESMO? Contact us to set up a meeting.
A mid-sized pharma was conducting a Phase III trial designed to support registration and launch of a radiopharmaceutical therapy in the US and sought support to rapidly assess and identify gaps in their evidence generation strategy and develop a mitigation plan.
A US biopharma needed to validate the patient journeys and US reimbursement pathways for their two alpha-emitting radioligand therapies in two solid tumor indications. They also sought to understand the suitable price points for each asset.
A European biotech specializing in the development of radioligand therapies (RLTs) sought to assess the sales potential of its drug candidate, considering the current and future market landscape, especially the positioning of prostate-specific membrane antigen-targeting RLTs.